Aliases & Classifications for Writing Disorder

Aliases & Descriptions for Writing Disorder:

Name: Writing Disorder 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060047

Summaries for Writing Disorder

Disease Ontology : 12 A learning disability that involves impaired written language ability such as impairments in handwriting, spelling, organization of ideas, and composition.

MalaCards based summary : Writing Disorder is related to dysgraphia and agraphia, and has symptoms including aprosodia An important gene associated with Writing Disorder is DCDC2 (Doublecortin Domain Containing 2). The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include testes, and related phenotypes are behavior/neurological and cellular

Related Diseases for Writing Disorder

Diseases related to Writing Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
id Related Disease Score Top Affiliating Genes
1 dysgraphia 11.1
2 agraphia 11.0
3 gata1-related thrombocytopenia 10.0 GRN PSEN1
4 hereditary paraganglioma-pheochromocytoma syndromes 10.0 GRN PSEN1
5 pancreatitis 10.0 GRN PSEN1
6 encephalitozoonosis 10.0 GRN PSEN1
7 cerebroretinal vasculopathy 10.0 GRN PSEN1
8 acquired metabolic disease 10.0 GRN PSEN1
9 hyperglycemia 10.0 GRN PSEN1
10 cerebral arteritis 9.9 PSEN1 TARDBP
11 urethritis 9.9 PSEN1 TARDBP
12 personality disorder 9.9 GRN PSEN1
13 autism spectrum disorder 9.9 DCDC2 GRN PSEN1
14 mitochondrial dna depletion syndrome 3 9.8 GRN TARDBP
15 acne inversa, familial, 3 9.8 PSEN1 TARDBP
16 social emotional agnosia 9.7 GRN PSEN1 TARDBP
17 color agnosia 9.7 GRN PSEN1 TARDBP
18 severe congenital nemaline myopathy 9.7 GRN PSEN1 TARDBP
19 andersen syndrome 9.7 GRN PSEN1 TARDBP
20 postauricular lymphadenitis 9.7 GRN PSEN1 TARDBP
21 adult mesenchymal chondrosarcoma 9.7 GRN PSEN1 TARDBP
22 pancreatic cancer/melanoma syndrome 9.7 GRN PSEN1 TARDBP
23 autoimmune disease of urogenital tract 9.7 GRN PSEN1 TARDBP
24 pancreatic solid pseudopapillary carcinoma 9.7 GRN PSEN1 TARDBP
25 coenzyme q10 deficiency, primary, 1 9.7 GRN PSEN1 TARDBP
26 angina pectoris 9.7 GRN PSEN1 TARDBP
27 cardiomyopathy, dilated, 1u 9.7 GRN PSEN1 TARDBP
28 eumycotic mycetoma 9.7 GRN PSEN1 TARDBP
29 substance-induced psychosis 9.7 GRN PSEN1 TARDBP
30 mucopolysaccharidosis iv 9.7 GRN TARDBP
31 asperger syndrome 9.6
32 long qt syndrome 5 9.6 GRN PSEN1 TARDBP
33 pediatric mesenchymal chondrosarcoma 9.6 GRN MAP4K5 PSEN1 TARDBP
34 acrofrontofacionasal dysostosis 9.5 GRN POU3F3 PSEN1 TARDBP
35 autoimmune disease of blood 9.2 DCDC2 GRN MAP4K5 POU3F3 PSEN1 TARDBP

Graphical network of the top 20 diseases related to Writing Disorder:



Diseases related to Writing Disorder

Symptoms & Phenotypes for Writing Disorder

UMLS symptoms related to Writing Disorder:


aprosodia

MGI Mouse Phenotypes related to Writing Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 DCDC2 GRN MAP4K5 PSEN1 TARDBP
2 cellular MP:0005384 9.35 GRN MAP4K5 POU3F3 PSEN1 TARDBP
3 nervous system MP:0003631 9.02 PSEN1 TARDBP DCDC2 GRN POU3F3

Drugs & Therapeutics for Writing Disorder

Drugs for Writing Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 255)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Denosumab Approved Phase 4 615258-40-7
9
Pamidronate Approved Phase 4 40391-99-9 4674
10
Zoledronic acid Approved Phase 4 118072-93-8 68740
11
Choline Approved, Nutraceutical Phase 4 62-49-7 305
12
Creatine Approved, Nutraceutical Phase 4 57-00-1 586
13 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Dopamine agonists Phase 4
17 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
19 Protective Agents Phase 4,Phase 1,Phase 2
20 Central Nervous System Depressants Phase 4,Phase 3
21 Anti-Infective Agents Phase 4,Phase 3,Phase 1
22 Hormone Antagonists Phase 4,Phase 3,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
25 Antipsychotic Agents Phase 4
26 Dopamine Antagonists Phase 4
27
Phosphocreatine Phase 4 67-07-2 587
28 Psychotropic Drugs Phase 4,Phase 1,Phase 2
29
Serotonin Phase 4,Phase 1,Phase 2 50-67-9 5202
30 Serotonin Agents Phase 4,Phase 1,Phase 2
31 Serotonin Antagonists Phase 4
32 Tranquilizing Agents Phase 4
33 Analgesics Phase 4,Phase 3
34 Anti-Anxiety Agents Phase 4
35 Anticonvulsants Phase 4,Phase 1,Phase 2
36 calcium channel blockers Phase 4
37 Calcium, Dietary Phase 4
38 Amoxicillin-Potassium Clavulanate Combination Phase 4
39 Anti-Bacterial Agents Phase 4,Phase 3
40 beta-Lactamase Inhibitors Phase 4
41 Clavulanic Acid Phase 4
42 Antiemetics Phase 4,Phase 3
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3
45 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
46 glucocorticoids Phase 4,Phase 3
47 Methylprednisolone acetate Phase 4
48 Methylprednisolone Hemisuccinate Phase 4
49 Neuroprotective Agents Phase 4,Phase 1,Phase 2
50 Prednisolone acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 343)
id Name Status NCT ID Phase
1 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4
2 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
3 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4
4 Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study Completed NCT00352196 Phase 4
5 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
6 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4
7 Acute Otitis Media (AOM) Therapy Trial in Young Children Completed NCT00377260 Phase 4
8 Adverse Drug Event Prevention Using Structured Pharmacist Review Completed NCT01467128 Phase 4
9 Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Completed NCT01467050 Phase 4
10 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4
11 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
12 Oral Prednisolone Dosing in Children Hospitalized With Asthma Completed NCT00257933 Phase 4
13 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases Recruiting NCT02721433 Phase 4
14 Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) Unknown status NCT01380938 Phase 3
15 Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents Completed NCT01219309 Phase 3
16 Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration Completed NCT00640445 Phase 2, Phase 3
17 Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. Completed NCT00145652 Phase 3
18 Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial Completed NCT00329992 Phase 3
19 Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Completed NCT01361997 Phase 3
20 ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia Completed NCT00396526 Phase 3
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Integrative Medicine Approach to the Management of Asthma in Adults Completed NCT00843544 Phase 2, Phase 3
23 Safety and Efficacy of Mirazid for Schistosomiasis Treatment Completed NCT01529710 Phase 3
24 Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation Completed NCT01994070 Phase 3
25 Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept Completed NCT00459706 Phase 3
26 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3
27 Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children Recruiting NCT03159104 Phase 3
28 Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors Recruiting NCT03177382 Phase 3
29 Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma Recruiting NCT02406144 Phase 3
30 The Effects of Trichosanthes Root on Blood Sugar in Patients With Diabetes Mellitus Recruiting NCT02855645 Phase 2, Phase 3
31 Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old Active, not recruiting NCT01916252 Phase 3
32 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
33 Online Support Groups for Depression and Anxiety Unknown status NCT01149265 Phase 1, Phase 2
34 Comparison of Methods for the Delivery of Interoceptive Exposure Unknown status NCT01201304 Phase 2
35 Expressive Arts as a Social and Community Integration Tool for Youth Recovering From Brain Injury Unknown status NCT00434603 Phase 1, Phase 2
36 Combined Treatment for Patients With Comorbid Substance Use Disorders and Post-traumatic Stress Disorder (PTSD): an Integration of Cognitive-behavioral Treatment (CBT) and Trauma-focused Structured Writing Therapy Completed NCT00763542 Phase 2
37 Exercise Interventions in Parkinson's Disease Completed NCT01439022 Phase 2
38 Study Targeting Affect Regulation Completed NCT01237366 Phase 1, Phase 2
39 Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp Completed NCT02015039 Phase 1, Phase 2
40 Propranolol in Post Traumatic Stress Disorder Completed NCT00465608 Phase 2
41 Building Complex Language Completed NCT01337232 Phase 1, Phase 2
42 Motor Training to Treat Hand Dystonia Completed NCT00021853 Phase 2
43 Transcranial Electrical Polarization to Treat Focal Hand Dystonia Completed NCT00106782 Phase 2
44 Girls In Recovery From Life Stress (GIRLS) Study Completed NCT00751946 Phase 2
45 Volitional Swallowing in Stroke Patients With Chronic Dysphagia Completed NCT00306501 Phase 2
46 Mothers Overcoming and Managing Stress Completed NCT00751244 Phase 2
47 Pain and Stress Management for People With Rheumatoid Arthritis Completed NCT00088764 Phase 2
48 Pioglitazone to Treat Fatty Liver in People With HIV Infection Completed NCT00441272 Phase 2
49 Positive Psychology Interventions in Individuals With Chronic Pain and Spinal Cord Injury Completed NCT02459028 Phase 2
50 Higher Dose Intradermal H5 Vaccine Completed NCT00439335 Phase 1, Phase 2

Search NIH Clinical Center for Writing Disorder

Genetic Tests for Writing Disorder

Anatomical Context for Writing Disorder

MalaCards organs/tissues related to Writing Disorder:

39
Testes

Publications for Writing Disorder

Articles related to Writing Disorder:

id Title Authors Year
1
The Ege Agraphia Test Battery for Identifying the Writing Disorders in Cases with Mild Cognitive Impairment and Alzheimer's Disease. ( 27711939 )
2016
2
Development of visual-motor perception in pupils with expressive writing disorder and pupils without expressive writing disorder: a comparative statistical analysis. ( 24791121 )
2013
3
Long-term psychosocial and health economy consequences of ADHD, autism, and reading-writing disorder: a prospective service evaluation project. ( 17968030 )
2008
4
Writing through the phonological buffer: a case of progressive writing disorder. ( 15949512 )
2005
5
Neurocognitive stability in Asperger syndrome, ADHD, and reading and writing disorder: a pilot study. ( 11263686 )
2001
6
Writing disorders in Italian aphasic patients. A multiple single-case study of dysgraphia in a language with shallow orthography. ( 9762960 )
1998
7
A model of writing performance: evidence from a dysgraphic patient with an "allographic" writing disorder. ( 4041261 )
1985

Variations for Writing Disorder

Expression for Writing Disorder

Search GEO for disease gene expression data for Writing Disorder.

Pathways for Writing Disorder

GO Terms for Writing Disorder

Biological processes related to Writing Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron migration GO:0001764 9.16 DCDC2 PSEN1
2 intracellular signal transduction GO:0035556 9.13 DCDC2 MAP4K5 PSEN1
3 negative regulation of protein phosphorylation GO:0001933 8.62 PSEN1 TARDBP

Sources for Writing Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....